Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference (RNAi). The company utilizes small interfering RNA (siRNA) to silence specific genes implicated in disease pathways. Its portfolio includes six approved medicines: AMVUTTRA (vutrisiran) and ONPATTRO (patisiran) for transthyretin-mediated amyloidosis; GIVLAARI (givosiran) for acute hepatic porphyria; OXLUMO (lumasiran) for primary hyperoxaluria type 1; Leqvio (inclisiran) for hypercholesterolemia; and Qfitlia (fitusiran) for hemophilia. Leqvio is developed and commercialized by collaborator Novartis, while Qfitlia is commercialized by Sanofi. Alnylam is also advancing next-generation candidates such as nucresiran for amyloidosis and zilebesiran for hypertension in collaboration with Roche. The company serves patients in the United States, European Union, United Kingdom, Japan, Brazil, and other global markets, focusing on both rare and prevalent diseases.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage alnylam.com
Sector Healthcare IR page investors.alnylam.com
Tags
rna interference, sirna therapeutics, rare diseases, cardiovascular disease, hematology, hepatology, nephrology, gene silencing, galnac conjugates, lipid nanoparticles, AMVUTTRA, vutrisiran, ONPATTRO, patisiran, GIVLAARI, givosiran, OXLUMO, lumasiran, Leqvio, inclisiran, Qfitlia, fitusiran, nucresiran, zilebesiran, Novartis, Sanofi, Genzyme, Roche, Genentech, Regeneron
Press page investors.alnylam.com/press-releases

Metrics

Valuation  
Market cap $ 20.382B
Market cap (USD) $ 20.382B
P/E 7.66
PEG —
P/BV 5.66
P/S 4.07
P/OCF 22.60
P/FCF 27.10
Dividend yield —
Turnover / mcap —
Returns  
ROE 73.3%
ROI 17.5%
ROIC 27.1%
Profit margin 8.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 127.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 50
Quality score 44.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004
Revenue 3.714B 2.248B 1.828B 1.037B 844.287M 492.853M 219.75M 74.908M — — — — — — — 100.041M — — — — — —
Net profit 313.747M -278.157M -440.242M -1.131B -852.824M -858.281M -886.116M -761.497M -490.874M -410.108M -290.073M -360.395M -89.225M -106.014M -57.649M -43.515M -47.59M -26.249M -85.466M -34.608M -42.914M —
Free cash flow 465.383M -42.589M 41.945M -613.333M -718.065M -685.322M -418.583M -689.503M -486.995M -372.258M -202.09M -174.602M -72.663M -123.957M -88.359M -89.073M -77.094M 54.727M 188.731M -29.616M -18.432M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004
Share price 397.65 235.31 191.41 237.65 169.58 129.97 115.17 72.91 127.05 37.44 94.14 97 64.31 18.25 8.07 9.95 17.67 34.23 31.89 20.71 — —
Price performance 12m 0.69 0.23 -0.19 0.4 0.3 0.13 0.58 -0.43 2.39 -0.6 -0.03 0.51 2.52 1.26 -0.19 -0.44 -0.48 0.07 0.54 — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 23.3M 34M 18.8M 43M 102M 199M 238M 328M 405M 778M
↳ YoY growth +181.2% +45.7% -44.8% +129.3% +138.1% +93.9% +19.8% +37.7% +23.6% +91.8%
↳ 5y CAGR +73.9% +218.3% +34.6% +1.5% +65.3% +53.5% +47.6% +77.2% +56.6% +50.0%
Lease liabilities (USD) — — 290M 304M 330M 322M 303M 285M 271M 271M
Cash and deposits (USD) 194M 645M 420M 547M 497M 820M 866M 813M 966M 1.66B
Right-of-use assets (USD) — — 230M 221M 241M 232M 215M 200M 191M 195M
Cash flow detail
Operating cash flow (USD) -308M -383M -563M -278M -615M -642M -541M 104M -8.31M 524M
Purchases of property, plant and equipment (USD) -64.6M -104M -127M -140M -70.4M -76.4M -72.1M -62.2M -34.3M -58.7M
Change in receivables (cash effect) (USD) -15M -10.7M 15.2M -24.2M -56.2M -102M -45.6M -87.9M -86.6M -360M
Change in inventories (cash effect) (USD) — 0.00 -22.6M -32.4M -35.4M -26.4M -34.1M 18.4M 13.6M 8.47M
Change in payables (cash effect) (USD) 10.1M -4.94M 15.5M 92.4M 144M 88.2M 192M 80.8M 91.1M 75.1M
Interest paid (cash effect) (USD) -1.1M -2.43M -775,000 -172,000 0.00 -24.7M -45.2M -32.1M -67.6M -219M
Income taxes paid (cash effect) (USD) -111,000 -114,000 -1.07M -2.57M — — -2.65M -6.02M -14.4M -15.1M
Share-based compensation (USD) 75.5M 92.8M 158M 175M 140M 166M 231M 222M 272M 348M
Operating cash flow before change in receivables (USD) -293M -372M -578M -254M -559M -540M -496M 192M 78.2M 884M
Free cash flow (OCF - PPE - intangibles) (USD) -372M -487M -690M -419M -685M -718M -613M 41.9M -42.6M 465M
Income detail
Research and development expense (USD) 382M 391M 505M 655M 655M 792M 883M 1B 1.13B 1.32B
↳ 5y CAGR +31.0% +35.2% +34.9% +28.1% +18.8% +15.7% +17.7% +14.7% +11.4% +15.0%
Total comprehensive income (USD) -448M -492M -760M -889M -865M -842M -1.14B -419M -289M 328M
Comprehensive income to owners (USD) -448M -492M -760M -889M -865M -842M -1.14B -419M -289M 328M
Reported Feb 15, 2017 Feb 13, 2020 May 2, 2019 Feb 13, 2020 Feb 10, 2022 Feb 10, 2022 Feb 13, 2025 Feb 13, 2025 Feb 13, 2025 Feb 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Nov 04, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, November 18, 2026, at 10:00 a.m. GMT (5:00 a.m. ET) in London.

A live audio webcast of the presentation will be available in the Investors section of the Company’s website at www.alnylam.com/events . A replay will be posted on the website within 48 hours after the event.

**About Alnylam Pharmaceuticals
**Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company develops transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel Prize-winning science of RNAi, achieving critical breakthroughs and bringing six medicines to approval. Its medicines are available in more than 70 countries, supported by a robust and rapidly expanding pipeline, and the Company is consistently recognized as an exceptional workplace and a socially responsible organization. Alnylam is executing its Alnylam 2030 strategy to accelerate innovation and scale its impact on human health. For more information, visit www.alnylam.com or follow Alnylam on X , LinkedIn , Facebook , Instagram , or YouTube .

**Alnylam Pharmaceuticals, Inc.
**
Bo Piela
(Media)
508-308-9783

Josh Brodsky
(Investors)
617-551-8276

Source: Alnylam Pharmaceuticals, Inc.

For Media Inquiries, please contact:

[email protected]

For Investor Inquiries, please contact:

[email protected]

MEDIA KIT
---------

Essential assets and documents related to Alnylam
VIEW ALL PRESS RELEASES
-----------------------

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

Copyright © 2026 Alnylam Pharmaceuticals, Inc. — All Rights Reserved

Nov 04, 2026

Board authorizes share repurchase program reflecting confidence in Alnylam's long-term growth prospects and commitment to disciplined capital allocation

Commercial leadership transition supports the Company's next phase of growth

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its Board of Directors has authorized a $1 billion share repurchase program and that the Company will transition to new commercial leadership as it enters its next phase of growth.

"Today we announced two important decisions, both of which demonstrate our conviction in Alnylam's future," said Amy Schulman, Chair of Alnylam's Board of Directors. "Alnylam has a distinctive and robust scientific foundation, a strong commercial opportunity and a fulsome pipeline. We will continue to focus on translating those strengths into sustained performance and long-term value for shareholders. Today’s repurchase authorization reflects our confidence in that future and our commitment to disciplined capital allocation. We are committed to continuing to evaluate opportunities to build on Alnylam’s strengths and create value for our shareholders."

$1 Billion Share Repurchase Program

Alnylam's Board of Directors has authorized the repurchase of up to $1 billion of the Company's common stock, reflecting its confidence in the Company's long-term growth prospects and its belief that the current share price does not fully reflect Alnylam's intrinsic value. Pursuant to this authorization, the Company expects to repurchase approximately $500 million of its common stock by the end of 2026 and the balance during 2027, subject to market conditions.

Returning capital to shareholders represents an important evolution in Alnylam's financial profile. Today's share repurchase authorization allows us to enhance shareholder returns while continuing to invest in our ongoing ATTR-CM launch, robust pipeline and select external innovation.

Commercial Leadership Transition

Alnylam also announced that Tolga Tanguler will depart his role as Chief Commercialization Officer. The Company is working with an executive search firm to support the selection of its next Chief Commercialization Officer and anticipates providing an update in due course.

During Mr. Tanguler's tenure, Alnylam significantly expanded its global commercial organization and marketed portfolio, establishing a strong foundation for future growth. As the Company looks ahead, it remains focused on expanding the reach of its medicines, building on its leadership in TTR and preparing for future launches.

"I'm grateful for Tolga’s leadership and the contributions he has made over the past several years," said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. "As we look ahead, we have significant opportunities to reach more patients with our medicines, advance our pipeline and continue building a sustainable, high-performing business."

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. For more information, please visit www.alnylam.com or follow Alnylam on X , LinkedIn , Facebook , Instagram , or YouTube .

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements regarding Alnylam’s expectations, beliefs, goals, plans or prospects, including, without limitation, statements regarding: Alnylam’s long-term growth prospects; Alnylam’s ability to build on its strengths, achieve sustained performance and create value for its shareholders; Alnylam’s ability to advance its pipeline and the potential it will pursue external innovation; the timing of Alnylam’s selection of its next Chief Commercialization Officer and any public announcement thereof; Alnylam’s ability to expand the reach of its medicines, build on its leadership in TTR, launch products in the future and continue to build a sustainable, high-performing business; the value of shares of Alnylam’s common stock that it will repurchase under its $1 billion share repurchase program, and the timing of any such repurchases; and Alnylam’s ability to achieve the goals in its Alnylam 2030 strategy. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam’s ability to successfully execute on its Alnylam 2030 strategy; Alnylam’s ability to successfully launch, market and sell Alnylam’s approved products globally, including AMVUTTRA; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam’s product candidates; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; delays, interruptions or failures in the manufacture and supply of Alnylam’s marketed products or its product candidates; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations; Alnylam’s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products; the outcome of litigation and government investigations; the risk of future litigation and government investigations; and unexpected expenditures; as well as those risks and uncertainties more fully discussed in the “Risk Factors” filed with Alnylam’s most recent periodic report (Quarterly Report on Form10-Q or Annual Report on Form 10-K) filed with the SEC and in its other SEC filings. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

Investor Relations
[email protected]

Media Relations
[email protected]

Source: Alnylam Pharmaceuticals, Inc.

For Media Inquiries, please contact:

[email protected]

For Investor Inquiries, please contact:

[email protected]

MEDIA KIT
---------

Essential assets and documents related to Alnylam
VIEW ALL PRESS RELEASES
-----------------------

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

Copyright © 2026 Alnylam Pharmaceuticals, Inc. — All Rights Reserved

Nov 03, 2026

– Late-Breaking Presentation at AHA Will Feature Long-Term Results from the HELIOS-B Phase 3 Study, Including Two Years of Open-Label Extension Data in Patients with ATTR-CM –

– HELIOS-B Post Hoc Analysis Demonstrates Positive Impact of AMVUTTRA in Preserving Exercise Capacity and Cardiopulmonary Performance –

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc . (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9 in Chicago, Illinois, and the International Symposium on Amyloidosis (ISA) 2026, taking place November 15-18 in Montevideo, Uruguay. The presentations add to the growing body of evidence demonstrating strength in RNAi-powered transthyretin (TTR) silencing with AMVUTTRA® (vutrisiran), including long-term cardiovascular outcomes and functional measures, while providing new insights into the multisystemic manifestations of transthyretin-mediated amyloidosis (ATTR) and opportunities for earlier diagnosis and treatment.

“Alnylam continues to pioneer TTR silencing through RNAi innovation, with an expanding evidence base that reinforces the potential of AMVUTTRA to transform ATTR care,” said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. “The landmark HELIOS-B study established a strong foundation for AMVUTTRA, and the research being presented at AHA and ISA reflects our determination to build on this progress and drive the next chapter in the treatment of this progressive disease.”

A highlight of the AHA program will be a late-breaking presentation of five-year results from the HELIOS-B Phase 3 study, including two years of open-label extension data evaluating long-term outcomes with vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). The findings will provide additional insights into the long-term clinical effects of RNAi-powered TTR silencing, including outcomes among patients receiving continuous vutrisiran treatment and those who initially received placebo before switching to vutrisiran.

A second late-breaking presentation of cardiopulmonary exercise testing (CPET) with imaging of 48 patients enrolled in HELIOS-B will show that treatment with vutrisiran preserved exercise capacity and cardiopulmonary performance during exercise over two years compared with placebo, providing mechanistic insight into the functional benefits of TTR silencing in ATTR-CM. An additional real-world evidence analysis of sex-related differences in ATTR may inform efforts to improve earlier diagnosis.

At ISA, a post hoc analysis of HELIOS-B will highlight statistically significant benefits of vutrisiran versus placebo on neuropathy-related quality-of-life measures among patients with ATTR-CM and evidence of polyneuropathy, further strengthening the body of data supporting TTR silencing across the multisystemic manifestations of ATTR amyloidosis in both hereditary and wild-type ATTR. Separately, real-world data from more than 1,000 patients initiating vutrisiran will demonstrate a higher prevalence of heart failure and greater comorbidity burden among second-line versus first-line initiators, supporting the rationale for initiating vutrisiran earlier in the treatment pathway. In addition, results from an indirect treatment comparison of vutrisiran versus acoramidis in ATTR-CM will be presented.

The AHA Scientific Sessions 2026 regular / non-late breaking abstracts are available here and ISA 2026 abstracts are available here . Alnylam will make the data presentations available on its Capella site.

AHA Scientific Sessions 2026 Presentation Details

Presentation Title Presenting Author Session Information
2-Year Results From the Open-Label Extension Period of the Phase 3 HELIOS-B Study of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy Sarah Cuddy Featured Science Monday, November 9, 2026, 9:40 am - 9:50 am CT Location: Learning Studio 2, Science and Technology Hall, South Hall Silencing ATTR-CM: Lessons from Helios-B and CARDIOTTRansform
The Effect of Vutrisiran on Exercise Capacity and Ventilatory Efficiency: Insights From the HELIOS-B CPET and Stress Echocardiography Subgroup Analysis Brinda Thillainathan Featured Science Monday, November 9, 2026, 9:50 am - 10:00 am CT Location: Learning Studio 2, Science and Technology Hall, South Hall Silencing ATTR-CM: Lessons from Helios-B and CARDIOTTRansform
Sex Differences at Diagnosis Among Patients With Hereditary or Wild-Type Transthyretin Amyloidosis: Analysis From the ConTTRibute Study Zubair Shah Abstract Poster Board Session Saturday, November 7, 2026,10:30 am - 11:30 am CT Poster Board: 4012 Mechanistic and Clinical Insights into Sex Differences in Cardiovascular Disease

ISA 2026 Presentation Details

Presentation Title Presenting Author Session Information
Treatment Effect of Vutrisiran on Measures of Polyneuropathy in HELIOS-B Yoshiki Sekijima Unmoderated Poster #242 Monday, November 16, 2026
Real-World Characteristics and Treatment Patterns Among New Vutrisiran Patients With ATTR-CM Sumeet Mitter Unmoderated Poster #209 Monday, November 16, 2026
Efficacy and Safety of Vutrisiran in South American Patients With Transthyretin Amyloidosis With Cardiomyopathy: Post Hoc Analysis of HELIOS-B Juan Costabel Unmoderated Poster #368 Tuesday, November 17, 2026
Comparative Efficacy of Vutrisiran and Acoramidis in ATTR-CM: A Matching-Adjusted Indirect Comparison Ronald Witteles Unmoderated Poster #526 Wednesday, November 18, 2026
Real-World Adherence and Persistence of Eplontersen in Patients with ATTR Sumeet Mitter Unmoderated Poster #569 Wednesday, November 18, 2026

AMVUTTRA® (vutrisiran) INDICATIONS AND IMPORTANT SAFETY INFORMATION

Indications Approved by the U.S. FDA

AMVUTTRA® (vutrisiran) is indicated for the treatment of the:

  • cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
  • polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

In a study of patients with hATTR-PN, the most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

In a study of patients with ATTR-CM, no new safety issues were identified.

For additional information about AMVUTTRA, please see the full U.S. Prescribing Information (revised March 2025)

The therapeutic indications described above are those approved by the U.S. FDA. AMVUTTRA is not currently registered in Uruguay.

About AMVUTTRA® (vutrisiran)

AMVUTTRA® (vutrisiran) demonstrates strength in RNAi-powered transthyretin (TTR) silencing, delivering rapid knockdown of TTR at the source of disease to address the underlying cause of transthyretin amyloidosis (ATTR). As ATTR is a rapidly progressive disease, even when patients may appear clinically stable, early treatment intervention is critical. In the HELIOS-B Phase 3 study, AMVUTTRA reduced the risk of all-cause mortality and recurrent CV events compared to placebo in the overall and monotherapy populations by 28.2% and 32.8%, respectively, through 36 months. It is the only TTR silencer approved for both the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) and cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in countries globally. More than 14,000 patients worldwide have been treated with AMVUTTRA, which is recommended by the European Society of Cardiology as a Class I, Level A treatment for patients with ATTR-CM. AMVUTTRA is administered once every three months via subcutaneous injection.

About Transthyretin Amyloidosis (ATTR)

Transthyretin amyloidosis (ATTR) is an underdiagnosed, rapidly progressive, debilitating, and fatal disease caused by pathogenic transthyretin (TTR) proteins, which accumulate as amyloid deposits in various parts of the body, including the nerves, heart, and gastrointestinal tract. Patients may present with polyneuropathy, cardiomyopathy, or both manifestations of disease. There are two different forms of ATTR – hereditary ATTR (hATTR), which is caused by a TTR gene variant, and wild-type ATTR (wtATTR), which occurs without a TTR gene variant. It is estimated that more than 500,000 people worldwide live with ATTR, with ~80% remaining undiagnosed.

About RNAi Technology

RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. For more information, please visit www.alnylam.com or follow Alnylam on X , LinkedIn , Facebook , Instagram , or YouTube .

Alnylam Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements regarding Alnylam’s expectations, beliefs, goals, plans or prospects, including, without limitation, statements regarding: Alnylam’s ability to pioneer TTR silencing through RNAi innovation; the potential of AMVUTTRA to transform ATTR care; Alnylam’s ability to build on its progress and drive the next chapter in the treatment of ATTR; the potential for the real-world evidence analysis of sex-related differences in ATTR to inform efforts to improve earlier diagnosis; and Alnylam’s ability to achieve the goals in its Alnylam 2030 strategy. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam’s ability to successfully execute on its Alnylam 2030 strategy; Alnylam’s ability to successfully launch, market and sell Alnylam’s approved products globally, including AMVUTTRA; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam’s product candidates; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; delays, interruptions or failures in the manufacture and supply of Alnylam’s marketed products or its product candidates; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations; Alnylam’s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products; the outcome of litigation and government investigations; the risk of future litigation and government investigations; and unexpected expenditures; as well as those risks and uncertainties more fully discussed in the “Risk Factors” filed with Alnylam’s most recent periodic report (Quarterly Report on Form10-Q or Annual Report on Form 10-K) filed with the SEC and in its other SEC filings. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

Alnylam Pharmaceuticals, Inc.

Sarah D’Souza
(Media)
[email protected]

Josh Brodsky
(Investors)
[email protected]

Source: Alnylam Pharmaceuticals, Inc.

For Media Inquiries, please contact:

[email protected]

For Investor Inquiries, please contact:

[email protected]

MEDIA KIT
---------

Essential assets and documents related to Alnylam
VIEW ALL PRESS RELEASES
-----------------------

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

Copyright © 2026 Alnylam Pharmaceuticals, Inc. — All Rights Reserved

Prompts

Alnylam Pharmaceuticals, Inc. (ticker ALNY), listed in United States.

ETFs Holding Alnylam Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
MEDX 3.42% 2,168 $ 652.633K Jun 30, 2026
TMED 2.60% 1,986 $ 597.846K Jun 30, 2026
FMED 2.33% 5,000 $ 1.203M Aug 31, 2026
HELX 1.96% 1,816 $ 546.67K Jun 30, 2026
LSEQ short -1.70% -1,770 $ -292.121K Nov 13, 2026
FEMG 1.67% 370 $ 111.381K Jun 30, 2026
JHAC 1.60% 188 $ 56.594K Jun 30, 2026
MID 1.46% 6,371 $ 1.533M Aug 31, 2026
HRTS 1.11% 2,566 $ 617.611K Aug 31, 2026
DWSH short -0.95% -374 $ -58.531K Nov 17, 2026
TCAF 0.93% 625,500 $ 99.911M Nov 17, 2026
JMID 0.71% 813 $ 167.088K Jul 31, 2026
CGGR 0.53% 842,007 $ 134.494M Nov 16, 2026
FMDE 0.52% 127,908 $ 38.504M Jun 30, 2026
UPSD 0.52% 2,959 $ 608.134K Jul 31, 2026
FDG 0.51% 8,940 $ 2.152M Aug 31, 2026
FELG 0.47% 88,675 $ 26.694M Jun 30, 2026
MKTN 0.47% 1,660 $ 499.71K Jun 30, 2026
FFLG 0.46% 13,244 $ 2.722M Jul 31, 2026
CGMM 0.42% 96,177 $ 15.362M Nov 16, 2026
CGBL 0.42% 211,264 $ 33.745M Nov 16, 2026
TCAL 0.33% 6,915 $ 1.105M Nov 17, 2026
MCDS 0.28% 143 $ 22.38K Nov 17, 2026
REMC 0.28% 31 $ 9,331.93 Jun 30, 2026
SMIZ 0.26% 2,908 $ 699.927K Aug 31, 2026
MODL 0.24% 8,258 $ 2.486M Jun 30, 2026
FEAC 0.24% 203 $ 61.109K Jun 30, 2026
ESLG 0.20% 221 $ 45.42K Jul 31, 2026
CLSE short -0.19% -7,051 $ -1.697M Aug 31, 2026
TUGN 0.19% 500 $ 150.515K Jun 30, 2026
TUG 0.18% 202 $ 60.808K Jun 30, 2026
AVMC 0.16% 5,577 $ 890.814K Nov 16, 2026
FBCG 0.14% 47,533 $ 9.769M Jul 31, 2026
ESLV 0.14% 94 $ 19.319K Jul 31, 2026
AVIE 0.13% 133 $ 21.244K Nov 16, 2026
WCEO 0.13% 63 $ 12.948K Jul 31, 2026
ESUM 0.13% 1,136 $ 233.471K Jul 31, 2026
JEPQ 0.12% 310,283 $ 48.559M Nov 17, 2026
PEPS 0.11% 108 $ 32.511K Jun 30, 2026
FTLS 0.09% 15,020 $ 0.00 Nov 16, 2026
JAVA 0.09% 43,347 $ 6.784M Nov 17, 2026
PHEQ 0.08% 388 $ 116.8K Jun 30, 2026
XMAG 0.05% 681 $ 106.679K Nov 13, 2026
NTSX 0.05% 2,234 $ 672.501K Jun 30, 2026
NTSD 0.04% 50 $ 15.052K Jun 30, 2026
APUE 0.04% 4,192 $ 1.009M Aug 31, 2026
GDE 0.04% 723 $ 174.019K Aug 31, 2026
VOXP 0.03% 9 $ 1,849.68 Jul 31, 2026
DUHP 0.03% 39,216 $ 6.143M Nov 12, 2026
RAA 0.03% 621 $ 186.94K Jun 30, 2026
ENHU 0.03% 17 $ 2,715.41 Nov 16, 2026
MSLC 0.03% 4,894 $ 1.178M Aug 31, 2026
TACU 0.03% 29 $ 4,632.17 Nov 17, 2026
DFAU 0.02% 19,680 $ 3.083M Nov 12, 2026
GVLU 0.02% 315 $ 50.315K Nov 17, 2026
DFUS 0.01% 18,211 $ 2.853M Nov 12, 2026
DFSU 0.01% 2,012 $ 315.18K Nov 12, 2026
DCOR 0.01% 30,016 $ 4.702M Nov 12, 2026
AVLC 0.01% 780 $ 124.589K Nov 16, 2026
DYNF 0.01% 28,410 $ 4.538M Nov 16, 2026
LCTU 0.01% 755 $ 120.596K Nov 16, 2026
DFAC 0.01% 50,326 $ 7.884M Nov 12, 2026
DXUV 0.00% 1,133 $ 177.484K Nov 12, 2026
CAML short 0.00% -32 $ -6,576.64 Jul 31, 2026
FLCG 0.00% 3 $ 722.07 Aug 31, 2026
AVUS 0.00% 522 $ 83.379K Nov 16, 2026
AVSU 0.00% 15 $ 2,395.95 Nov 16, 2026
IALT 0.00% 1,258 $ 200.94K Nov 16, 2026